Patients over age 65 with myelodysplastic syndromes (MDS) should be considered transplant eligible, according to an oral presentation at the 2015 ASH Annual Meeting. Investigators reported the results of a multi-center, prospective study comparing HCT outcomes of 592 patients with MDS age 55-64 years and 688 patients age ≥65 years who underwent HCT between 2010-2014. Two-year overall survival was comparable in patients age 55-64 years vs. patients age ≥65 years: 46% vs. 42%, respectively (p=0.1). Transplants were between 2010 and 2014 reported to CIBMTR (Center for International Blood and Marrow Transplant Research), and the 688 patients age ≥65 years were Medicare-eligible patients enrolled in a CIBMTR-sponsored coverage with evidence development (CED) clinical trial approved by the Centers for Medicare and Medicaid services.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Patients Age 65 Years and Older with MDS Should Not Be Limited from Undergoing HCT
Dec 2015